JP7695187B2 - HPTP-β(VE-PTP)およびVEGFを標的にする多特異性抗体 - Google Patents
HPTP-β(VE-PTP)およびVEGFを標的にする多特異性抗体 Download PDFInfo
- Publication number
- JP7695187B2 JP7695187B2 JP2021516373A JP2021516373A JP7695187B2 JP 7695187 B2 JP7695187 B2 JP 7695187B2 JP 2021516373 A JP2021516373 A JP 2021516373A JP 2021516373 A JP2021516373 A JP 2021516373A JP 7695187 B2 JP7695187 B2 JP 7695187B2
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- compound
- disclosure comprises
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025030114A JP2025098019A (ja) | 2018-09-24 | 2025-02-27 | HPTP-β(VE-PTP)およびVEGFを標的にする多特異性抗体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862735331P | 2018-09-24 | 2018-09-24 | |
| US62/735,331 | 2018-09-24 | ||
| US201962832461P | 2019-04-11 | 2019-04-11 | |
| US62/832,461 | 2019-04-11 | ||
| PCT/US2019/052405 WO2020068653A1 (en) | 2018-09-24 | 2019-09-23 | MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025030114A Division JP2025098019A (ja) | 2018-09-24 | 2025-02-27 | HPTP-β(VE-PTP)およびVEGFを標的にする多特異性抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022502367A JP2022502367A (ja) | 2022-01-11 |
| JP2022502367A5 JP2022502367A5 (cg-RX-API-DMAC7.html) | 2022-10-03 |
| JP7695187B2 true JP7695187B2 (ja) | 2025-06-18 |
Family
ID=69885319
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021516373A Active JP7695187B2 (ja) | 2018-09-24 | 2019-09-23 | HPTP-β(VE-PTP)およびVEGFを標的にする多特異性抗体 |
| JP2025030114A Withdrawn JP2025098019A (ja) | 2018-09-24 | 2025-02-27 | HPTP-β(VE-PTP)およびVEGFを標的にする多特異性抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025030114A Withdrawn JP2025098019A (ja) | 2018-09-24 | 2025-02-27 | HPTP-β(VE-PTP)およびVEGFを標的にする多特異性抗体 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US10894824B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3856245A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7695187B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN120058958A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020068653A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2828739T3 (es) | 2006-04-07 | 2021-05-27 | Aerpio Pharmaceuticals Inc | Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos |
| MX363351B (es) | 2011-10-13 | 2019-03-20 | Aerpio Therapeutics Inc | Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular. |
| EP3501536B1 (en) * | 2011-10-13 | 2025-12-24 | EyePoint Pharmaceuticals, Inc. | Treatment of ocular disease |
| WO2015200905A2 (en) | 2014-06-28 | 2015-12-30 | Oligasis, Llc | Dual pdgf/vegf antagonists |
| IL290457B2 (en) | 2015-12-30 | 2025-02-01 | Kodiak Sciences Inc | Antibodies and their conjugates |
| SG10201912556VA (en) | 2016-07-20 | 2020-02-27 | Aerpio Therapeutics Inc | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) |
| CA3092588A1 (en) | 2018-03-02 | 2019-09-06 | Kodiak Sciences Inc. | Il-6 antibodies and fusion constructs and conjugates thereof |
| EP3856245A4 (en) | 2018-09-24 | 2022-10-26 | EyePoint Pharmaceuticals, Inc. | MULTISPECIFIC ANTIBODIES AGAINST HPTP - BETA (VE-PTP) AND VEGF |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| WO2022190016A1 (en) * | 2021-03-09 | 2022-09-15 | Molecular Partners Ag | Novel darpin based multi-specific t-cell engagers |
| CA3228501A1 (en) * | 2021-08-09 | 2023-02-16 | Sicong DONG | Bispecific fusion polypeptide and application thereof |
| US20250002599A1 (en) * | 2021-09-03 | 2025-01-02 | Novarock Biotherapeutics, Ltd. | Bispecific and trispecific binding proteins to pd-l1, cd137, and/or tgf-beta and uses thereof |
| AU2023206363A1 (en) * | 2022-01-13 | 2024-08-15 | Ingenia Therapeutics Inc. | Vegf and tie2-binding fusion protein and uses thereof |
| EP4537856A4 (en) * | 2022-06-07 | 2026-08-19 | Chengdu Origen Biotechnology Co Ltd | Pharmaceutical Composition of Adeno-Associated Virus and Associated Use |
| CN116715749B (zh) * | 2023-03-20 | 2024-04-09 | 吉林大学 | 一种与胶原具有特异结合能力vegf活性抑制蛋白及其制备方法与应用 |
| CN118853712A (zh) * | 2023-04-28 | 2024-10-29 | 成都弘基生物科技有限公司 | 编码抗vegf蛋白的核酸、多核苷酸表达盒及重组腺相关病毒 |
| KR20260105762A (ko) * | 2023-11-15 | 2026-07-07 | 청두 오리젠 바이오테크놀로지 씨오., 엘티디. | 재조합 아데노 관련 바이러스 약학적 조성물 및 이의 용도 |
| CN121910909B (zh) * | 2026-03-27 | 2026-06-12 | 中国医学科学院病原生物学研究所 | 工程化多肽注射系统及其在靶向递送抗菌肽中的用途 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012504943A (ja) | 2008-10-08 | 2012-03-01 | エフ.ホフマン−ラ ロシュ アーゲー | 二重特異的抗−vegf/抗−ang−2抗体 |
| WO2018017714A1 (en) | 2016-07-20 | 2018-01-25 | Aerpio Therapeutics, Inc. | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) |
| JP2018505167A (ja) | 2015-01-28 | 2018-02-22 | イーライ リリー アンド カンパニー | VEGFA/Ang2化合物 |
Family Cites Families (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| JPH07503132A (ja) | 1991-12-17 | 1995-04-06 | ジェンファーム インターナショナル,インコーポレイティド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
| US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
| CA2216963C (en) | 1995-04-06 | 2010-06-22 | Regeneron Pharmaceuticals, Inc. | Tie-2 ligands, methods of making and uses thereof |
| US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
| DE69829891T2 (de) | 1997-04-07 | 2005-10-06 | Genentech, Inc., South San Francisco | Anti-VEGF Antikörper |
| US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| US6316109B1 (en) | 2000-09-21 | 2001-11-13 | Ppg Industries Ohio, Inc. | Aminoplast-based crosslinkers and powder coating compositions containing such crosslinkers |
| CN1318093C (zh) | 2001-09-28 | 2007-05-30 | 参天制药株式会社 | 含与聚乙二醇结合的药物的眼组织注射剂 |
| US20030158083A1 (en) | 2002-02-08 | 2003-08-21 | The Procter & Gamble Company | Method of effecting angiogenesis by modulating the function of a novel endothelia phosphatase |
| US20030215899A1 (en) | 2002-02-13 | 2003-11-20 | Ceptyr, Inc. | Reversible oxidation of protein tyrosine phosphatases |
| US7507568B2 (en) | 2002-09-25 | 2009-03-24 | The Proctor & Gamble Company | Three dimensional coordinates of HPTPbeta |
| US7226755B1 (en) | 2002-09-25 | 2007-06-05 | The Procter & Gamble Company | HPTPbeta as a target in treatment of angiogenesis mediated disorders |
| US7758859B2 (en) | 2003-08-01 | 2010-07-20 | Genentech, Inc. | Anti-VEGF antibodies |
| US20050059639A1 (en) | 2003-09-11 | 2005-03-17 | Wei Edward T. | Ophthalmic compositions and method for treating eye discomfort and pain |
| KR101166342B1 (ko) | 2004-03-15 | 2012-07-18 | 얀센 파마슈티카 엔.브이. | 아편계 약물 수용체 조절자로서의 신규의 화합물 |
| CN101163501A (zh) | 2005-02-23 | 2008-04-16 | 梅里麦克制药股份有限公司 | 调节生物活性的双特异性结合剂 |
| US20120237442A1 (en) | 2005-04-06 | 2012-09-20 | Ibc Pharmaceuticals, Inc. | Design and Construction of Novel Multivalent Antibodies |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US20070154482A1 (en) | 2005-09-12 | 2007-07-05 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state |
| CA2622772A1 (en) | 2005-09-29 | 2007-04-12 | Viral Logic Systems Technology Corp. | Immunomodulatory compositions and uses therefor |
| EP1962903B1 (en) | 2005-12-15 | 2013-03-13 | MedImmune Limited | Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer |
| CA2622312A1 (en) | 2006-01-30 | 2007-08-02 | (Osi) Eyetech, Inc. | Combination therapy for the treatment of neovascular disorders |
| ES2828739T3 (es) | 2006-04-07 | 2021-05-27 | Aerpio Pharmaceuticals Inc | Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos |
| CA2654510C (en) | 2006-06-16 | 2015-03-17 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations suitable for intravitreal administration |
| US8846685B2 (en) | 2006-06-27 | 2014-09-30 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
| US7589212B2 (en) | 2006-06-27 | 2009-09-15 | Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US7795444B2 (en) | 2006-06-27 | 2010-09-14 | Warner Chilcott Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US10259860B2 (en) * | 2007-02-27 | 2019-04-16 | Aprogen Inc. | Fusion proteins binding to VEGF and angiopoietin |
| US20100256147A1 (en) | 2007-04-13 | 2010-10-07 | Hangauer Jr David G | Biaryl acetamide derivatives as modulators of the kinase cascade for the treatment of hearing loss, osteoporosis and cell proliferation disorders |
| JP2010531896A (ja) | 2007-06-26 | 2010-09-30 | チルドレンズ メディカル センター コーポレーション | 治療的投与のためのMetAP−2阻害剤ポリマーソーム |
| ES2540854T3 (es) | 2007-06-29 | 2015-07-14 | Merck Sharp & Dohme Corp. | Usos de antagonistas MDL-1 |
| RU2010120674A (ru) | 2007-10-22 | 2011-11-27 | Шеринг Корпорейшн (US) | Полностью человеческие анти-vegf-антитела и способы их применения |
| CA2716347C (en) | 2008-02-21 | 2017-06-20 | Sequoia Pharmaceuticals, Inc. | Amino acid inhibitors of cytochrome p450 |
| US8293714B2 (en) | 2008-05-05 | 2012-10-23 | Covx Technology Ireland, Ltd. | Anti-angiogenic compounds |
| KR20180005753A (ko) | 2008-06-25 | 2018-01-16 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | Vegf를 억제하는 안정하고 가용성인 항체 |
| NZ592591A (en) | 2008-11-03 | 2012-04-27 | Molecular Partners Ag | Binding proteins comprising ankyrin repeast domains that inhibit the vegf-a receptor interaction |
| PT2385763T (pt) | 2009-01-12 | 2018-07-13 | Aerpio Therapeutics Inc | Métodos para tratar o síndrome de extravasamento vascular |
| US9096555B2 (en) | 2009-01-12 | 2015-08-04 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome |
| US8883832B2 (en) | 2009-07-06 | 2014-11-11 | Aerpio Therapeutics Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
| BRPI1006897A2 (pt) | 2009-07-06 | 2015-09-08 | Akebia Therapeutics Inc | compostos, composições e métodos de prevenção da metástase de células cancerosas. |
| CA2774039A1 (en) | 2009-11-06 | 2011-05-12 | Aerpio Therapeutics Inc. | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha |
| CA3040276A1 (en) | 2009-12-02 | 2011-06-09 | Imaginab, Inc. | J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use |
| ES2468827T3 (es) | 2010-01-14 | 2014-06-17 | Sanwa Kagaku Kenkyusho Co., Ltd | Producto farmacéutico para prevenir o tratar trastornos acompañados de angiog�nesis ocular y/o permeabilidad vascular ocular elevada |
| US8993524B2 (en) | 2010-03-05 | 2015-03-31 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| TWI510246B (zh) | 2010-04-30 | 2015-12-01 | Molecular Partners Ag | 抑制vegf-a受體交互作用的經修飾結合性蛋白質 |
| US20180092883A1 (en) | 2010-10-07 | 2018-04-05 | Aerpio Therapeutics, Inc. | Phosphatase inhibitors for treating ocular diseases |
| CA2818215C (en) | 2010-10-07 | 2015-07-21 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular edema, neovascularization and related diseases |
| KR20180023015A (ko) | 2011-01-13 | 2018-03-06 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
| MX363351B (es) | 2011-10-13 | 2019-03-20 | Aerpio Therapeutics Inc | Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular. |
| EP3501536B1 (en) | 2011-10-13 | 2025-12-24 | EyePoint Pharmaceuticals, Inc. | Treatment of ocular disease |
| PT2846836T (pt) | 2012-05-07 | 2019-10-29 | Allergan Inc | Método de tratamento de dmi em doentes refratários à terapia anti-vegf |
| SI3495387T1 (sl) | 2012-07-13 | 2021-12-31 | Roche Glycart Ag | Bispecifična protitelesa proti VEGF/proti ANG-2 in njihova uporaba pri zdravljenju bolezni očesnih žil |
| WO2014033184A1 (en) | 2012-08-28 | 2014-03-06 | Novartis Ag | Use of a vegf antagonist in treating ocular vascular proliferative diseases |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| JP6572201B2 (ja) | 2013-03-15 | 2019-09-04 | エアーピオ セラピューティクス インコーポレイテッド | 眼疾患を処置するための組成物、製剤、および方法 |
| US10617755B2 (en) | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
| MX377714B (es) | 2013-10-18 | 2025-03-11 | Regeneron Pharma | Composiciones que comprenden una combinación de un antagonista de vegf y un anticuerpo anti-ctla-a. |
| EP3628324A1 (en) | 2013-11-05 | 2020-04-01 | Allergan, Inc. | Method of treating conditions of the eye with an anti-vegf darpin |
| SG11201605580RA (en) | 2014-01-10 | 2016-10-28 | Anaptysbio Inc | Antibodies directed against interleukin-33 (il-33) |
| CN105026433B (zh) * | 2014-01-24 | 2018-10-19 | 上海恒瑞医药有限公司 | VEGF与PDGFRβ双特异性融合蛋白及其用途 |
| US9719135B2 (en) | 2014-07-03 | 2017-08-01 | Mannin Research Inc. | Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system |
| US9539245B2 (en) | 2014-08-07 | 2017-01-10 | Aerpio Therapeutics, Inc. | Combination of immunotherapies with activators of Tie-2 |
| TN2017000066A1 (en) | 2014-09-16 | 2018-07-04 | Ovascience Inc | Anti-vasa antibodies, and methods of production and use thereof. |
| US20160082129A1 (en) | 2014-09-24 | 2016-03-24 | Aerpio Therapeutics, Inc. | VE-PTP Extracellular Domain Antibodies Delivered by a Gene Therapy Vector |
| TWI806150B (zh) * | 2014-11-07 | 2023-06-21 | 瑞士商諾華公司 | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 |
| CN106999511A (zh) | 2014-12-11 | 2017-08-01 | 拜耳医药保健有限责任公司 | 具有小的活动性脉络膜新生血管病变的年龄相关性黄斑变性的治疗 |
| WO2016115092A1 (en) | 2015-01-12 | 2016-07-21 | La Jolla Institute For Allergy And Immunology | Methods for targeting host vascular mechanism for therapeutic protection against hemorrhagic fever |
| US9458211B1 (en) | 2015-04-02 | 2016-10-04 | Molecular Partners Ag | Recombinant proteins that simultaneously bind HGF, VEGF-A and serum albumin, comprising ankyrin repeat domains |
| US11091559B2 (en) | 2015-08-27 | 2021-08-17 | Celldex Therapeutics, Inc. | Anti-ALK antibodies and methods for use thereof |
| JP6959912B2 (ja) | 2015-09-23 | 2021-11-05 | ジェネンテック, インコーポレイテッド | 抗vegf抗体の最適化変異体 |
| CN109069638B (zh) | 2016-03-24 | 2022-03-29 | 璟尚生物制药公司 | 用于癌症治疗的三特异性抑制剂 |
| JP6983824B2 (ja) | 2016-07-04 | 2021-12-17 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 新規抗体フォーマット |
| WO2018067646A1 (en) | 2016-10-04 | 2018-04-12 | Asclepix Therapeutics, Llc | Compounds and methods for activating tie2 signaling |
| IT201600120314A1 (it) | 2016-11-28 | 2018-05-28 | Nuovo Pignone Tecnologie Srl | Turbo-compressore e metodo di funzionamento di un turbo-compressore |
| US10426817B2 (en) | 2017-01-24 | 2019-10-01 | Macregen, Inc. | Treatment of age-related macular degeneration and other eye diseases with apolipoprotein mimetics |
| US20200140547A1 (en) | 2017-05-26 | 2020-05-07 | The Johns Hopkins University | Multifunctional antibody-ligand traps to modulate immune tolerance |
| TW201904610A (zh) | 2017-06-14 | 2019-02-01 | 德商拜耳製藥公司 | 用於治療新生血管型青光眼之非抗體vegf拮抗劑 |
| CN107602702A (zh) | 2017-09-22 | 2018-01-19 | 生标(上海)医疗器械科技有限公司 | 一种同时靶向人p185和血管内皮生长因子的抗体及其应用 |
| KR20200093621A (ko) | 2017-11-30 | 2020-08-05 | 리제너론 파아마슈티컬스, 인크. | 혈관형성 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
| EP3758735B1 (en) | 2018-02-28 | 2023-12-13 | AP Biosciences, Inc. | Bifunctional proteins combining checkpoint blockade for targeted therapy |
| MX2020009140A (es) | 2018-03-16 | 2020-09-28 | Novartis Ag | Metodos para el tratamiento de enfermedades oculares. |
| US10276202B1 (en) | 2018-04-23 | 2019-04-30 | Western Digital Technologies, Inc. | Heat-assisted magnetic recording (HAMR) medium with rhodium or rhodium-based alloy heat-sink layer |
| RS67656B1 (sr) | 2018-05-10 | 2026-02-27 | Regeneron Pharma | Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora |
| CA3100349A1 (en) | 2018-05-17 | 2019-11-21 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor inhibition by phosphatase recruitment |
| US11066476B2 (en) | 2018-09-14 | 2021-07-20 | Shanghai tongji hospital | Asymmetric bispecific antibody |
| EP3856245A4 (en) | 2018-09-24 | 2022-10-26 | EyePoint Pharmaceuticals, Inc. | MULTISPECIFIC ANTIBODIES AGAINST HPTP - BETA (VE-PTP) AND VEGF |
-
2019
- 2019-09-23 EP EP19867311.3A patent/EP3856245A4/en active Pending
- 2019-09-23 CN CN202510236262.6A patent/CN120058958A/zh active Pending
- 2019-09-23 CN CN201980077336.9A patent/CN113164597B/zh active Active
- 2019-09-23 US US16/579,078 patent/US10894824B2/en active Active
- 2019-09-23 WO PCT/US2019/052405 patent/WO2020068653A1/en not_active Ceased
- 2019-09-23 JP JP2021516373A patent/JP7695187B2/ja active Active
-
2020
- 2020-12-10 US US17/117,993 patent/US11873334B2/en active Active
-
2023
- 2023-12-05 US US18/528,957 patent/US12398204B2/en active Active
-
2025
- 2025-02-27 JP JP2025030114A patent/JP2025098019A/ja not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012504943A (ja) | 2008-10-08 | 2012-03-01 | エフ.ホフマン−ラ ロシュ アーゲー | 二重特異的抗−vegf/抗−ang−2抗体 |
| JP2018505167A (ja) | 2015-01-28 | 2018-02-22 | イーライ リリー アンド カンパニー | VEGFA/Ang2化合物 |
| WO2018017714A1 (en) | 2016-07-20 | 2018-01-25 | Aerpio Therapeutics, Inc. | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) |
Non-Patent Citations (1)
| Title |
|---|
| Campochiaro. P. et al.,Targeting Tie2 for Treatment of Diabetic Retinopathy and Diabetic Macular Edema,Current Diabetes Reports,2016年,Vol.16, No.126,pp.1-11 |
Also Published As
| Publication number | Publication date |
|---|---|
| US12398204B2 (en) | 2025-08-26 |
| JP2022502367A (ja) | 2022-01-11 |
| CN113164597A (zh) | 2021-07-23 |
| US20240174740A1 (en) | 2024-05-30 |
| CN113164597B (zh) | 2025-02-28 |
| WO2020068653A1 (en) | 2020-04-02 |
| US20210171618A1 (en) | 2021-06-10 |
| US10894824B2 (en) | 2021-01-19 |
| US11873334B2 (en) | 2024-01-16 |
| CN120058958A (zh) | 2025-05-30 |
| EP3856245A4 (en) | 2022-10-26 |
| US20200095309A1 (en) | 2020-03-26 |
| JP2025098019A (ja) | 2025-07-01 |
| EP3856245A1 (en) | 2021-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025098019A (ja) | HPTP-β(VE-PTP)およびVEGFを標的にする多特異性抗体 | |
| JP7107914B2 (ja) | VE-PTP(HPTP-β)を標的化するヒト化モノクローナル抗体 | |
| AU2012323849B2 (en) | Treatment of ocular disease | |
| KR101314014B1 (ko) | 신규한 항-plgf 항체 | |
| JP7826279B2 (ja) | 抗ベータセルリン抗体、その断片、及び多重特異性結合分子 | |
| KR102497171B1 (ko) | 항-안지오포이에틴-2(Ang2) 항체 및 그의 용도 | |
| JP2016502850A (ja) | ヒアルロナンに結合するペプチドタグを使用する組成物及び方法 | |
| JP2022502367A5 (cg-RX-API-DMAC7.html) | ||
| WO2023001288A1 (zh) | 整合素GPIIb/IIIa拮抗剂及其和抗VEGF抗体联合用药的应用 | |
| JP2025011251A (ja) | 眼の疾患の処置のためのアゴニスト性TrkB結合分子 | |
| CN116964088A (zh) | 用于治疗肺动脉高压(pah)的抗pdgf-b抗体和使用方法 | |
| TW202604956A (zh) | Ang2/vegf 雙特異性結合分子 | |
| HK40126782A (en) | C5/vegf bispecific binding molecules | |
| TW202608920A (zh) | 靶向血管生成因子之多特異性融合蛋白 | |
| BR112023000482B1 (pt) | Moléculas de ligação multiespecíficas, composição farmacêutica e kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20220331 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220922 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220922 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230818 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230829 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231128 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240115 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240329 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240701 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20241029 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250227 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250509 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250606 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7695187 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |